Article Details
Retrieved on: 2021-04-06 08:48:45
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
NHS cost regulators have backed funding for Alexion's Ondexxya (andexanet alfa) to reverse anticoagulation of the direct factor Xa (FXa) inhibitors ...
Article found on: www.pharmatimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here